LBA
PLRX icon

Letko, Brosseau & Associates’s Pliant Therapeutics PLRX Stock Holding History

Letko, Brosseau & Associates’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,400
Closed -$14K – 97
2025
Q1 		$14K Hold
10,400
– – ﹤0.01% 88
2024
Q4 		$137K Hold
10,400
– – ﹤0.01% 95
2024
Q3 		$117K Buy
+10,400
New +$130K ﹤0.01% 97

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Letko, Brosseau & Associates's PLRX Position: Q2 2025 in Review

Letko, Brosseau & Associates sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 10,400 shares — an estimated $14K sold.

Letko, Brosseau & Associates first reported a position in PLRX in Q3 2024 and held it in 3 quarters. The position peaked at $137K in Q4 2024. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Letko, Brosseau & Associates reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 10,400 Pliant Therapeutics shares in Q2 2025, an estimated $14K.
  • Letko, Brosseau & Associates first reported a position in Pliant Therapeutics in Q3 2024 and held it in 3 quarters.
  • Letko, Brosseau & Associates's Pliant Therapeutics position peaked at $137K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2025, filed 8 Aug 2025.